Triplet Therapeutics
Jia joined Triplet Therapeutics, Inc. as Director of Program Management in August 2020. He brings over 10 years of experience in nucleic acid drug discovery and development across various biotechnology organizations. Prior to joining Triplet, Jia was Associate Director of Program and Portfolio Management at Translate Bio where he was responsible for managing and guiding cross-functional project and platform teams on efforts ranging from target identification to clinical development of mRNA therapeutics. He received his degree in Biotechnology from Rochester Institute of Technology.
This person is not in any teams
This person is not in any offices
Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.